Clinical Evolution and Risk Factors in Patients Infected during the First Wave of COVID-19 : A Two-Year Longitudinal Study
A limited number of longitudinal studies have examined the symptoms associated with long-COVID-19. We conducted an assessment of symptom onset, severity and patient recovery, and determined the percentage of patients who experienced reinfection up to 2 years after the initial onset of the disease. Our cohort comprises 377 patients (≥18 years) with laboratory-confirmed COVID-19 in a secondary hospital (Madrid, Spain), throughout March 3-16, 2020. Disease outcomes and clinical data were followed-up until August 12, 2022. We reviewed the evolution of the 253 patients who had survived as of April 2020 (67.1%). Nine died between April 2020 and August 2022. A multivariate regression analysis performed to detect the risk factors associated with long-COVID-19 revealed that the increased likelihood was associated with chronic obstructive lung disease (OR 14.35, 95% CI 1.89-109.09; p = 0.010), dyspnea (5.02, 1.02-24.75; p = 0.048), higher LDH (3.23, 1.34-7.52; p = 0.006), and lower D-dimer levels (0.164, 0.04-0.678; p = 0.012). Reinfected patients (n = 45) (47.8 years; 39.7-67.2) were younger than non-reinfected patients (64.1 years; 48.6-74.4)) (p < 0.001). Patients who received a combination of vaccines exhibited fewer symptoms (44.4%) compared to those who received a single type of vaccine (77.8%) (p = 0.048). Long-COVID-19 was detected in 27.05% (66/244) of patients. The early detection of risk factors helps predict the clinical course of patients with COVID-19. Middle-aged adults could be susceptible to reinfection, highlighting the importance of prevention and control measures regardless of vaccination status.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Tropical medicine and infectious disease - 8(2023), 7 vom: 25. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rescalvo-Casas, Carlos [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Coronavirus disease 2019 |
|---|
| Anmerkungen: |
Date Revised 01.08.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/tropicalmed8070340 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360055346 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360055346 | ||
| 003 | DE-627 | ||
| 005 | 20231226082209.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/tropicalmed8070340 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360055346 | ||
| 035 | |a (NLM)37505636 | ||
| 035 | |a (PII)340 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rescalvo-Casas, Carlos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Evolution and Risk Factors in Patients Infected during the First Wave of COVID-19 |b A Two-Year Longitudinal Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a A limited number of longitudinal studies have examined the symptoms associated with long-COVID-19. We conducted an assessment of symptom onset, severity and patient recovery, and determined the percentage of patients who experienced reinfection up to 2 years after the initial onset of the disease. Our cohort comprises 377 patients (≥18 years) with laboratory-confirmed COVID-19 in a secondary hospital (Madrid, Spain), throughout March 3-16, 2020. Disease outcomes and clinical data were followed-up until August 12, 2022. We reviewed the evolution of the 253 patients who had survived as of April 2020 (67.1%). Nine died between April 2020 and August 2022. A multivariate regression analysis performed to detect the risk factors associated with long-COVID-19 revealed that the increased likelihood was associated with chronic obstructive lung disease (OR 14.35, 95% CI 1.89-109.09; p = 0.010), dyspnea (5.02, 1.02-24.75; p = 0.048), higher LDH (3.23, 1.34-7.52; p = 0.006), and lower D-dimer levels (0.164, 0.04-0.678; p = 0.012). Reinfected patients (n = 45) (47.8 years; 39.7-67.2) were younger than non-reinfected patients (64.1 years; 48.6-74.4)) (p < 0.001). Patients who received a combination of vaccines exhibited fewer symptoms (44.4%) compared to those who received a single type of vaccine (77.8%) (p = 0.048). Long-COVID-19 was detected in 27.05% (66/244) of patients. The early detection of risk factors helps predict the clinical course of patients with COVID-19. Middle-aged adults could be susceptible to reinfection, highlighting the importance of prevention and control measures regardless of vaccination status | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a coronavirus disease 2019 | |
| 650 | 4 | |a long-COVID-19 | |
| 650 | 4 | |a reinfection | |
| 650 | 4 | |a risk factors | |
| 650 | 4 | |a vaccines | |
| 700 | 1 | |a Pérez-Tanoira, Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a Villegas, Rocío Fernández |e verfasserin |4 aut | |
| 700 | 1 | |a Hernando-Gozalo, Marcos |e verfasserin |4 aut | |
| 700 | 1 | |a Seijas-Pereda, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-García, Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Moríñigo, Helena Moza |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Herruz, Peña |e verfasserin |4 aut | |
| 700 | 1 | |a Arroyo, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a González, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Expósito, Cristina Verdú |e verfasserin |4 aut | |
| 700 | 1 | |a Lledó García, Lourdes |e verfasserin |4 aut | |
| 700 | 1 | |a Cabrera, Juan Romanyk |e verfasserin |4 aut | |
| 700 | 1 | |a Cuadros-González, Juan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tropical medicine and infectious disease |d 2016 |g 8(2023), 7 vom: 25. Juni |w (DE-627)NLM275181960 |x 2414-6366 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:7 |g day:25 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/tropicalmed8070340 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 7 |b 25 |c 06 | ||